This prospective longitudinal study investigated the impact of CTLA4-Ig treatment on peripheral blood-derived CD4pos cells in RA patients in terms of cell phenotype and cytokine milieu involved in the unbalanced inflammatory cascade of the disease and their potential role as a prognostic biomarker of treatment response. The gene discussed is CTLA4; the disease is rheumatoid arthritis.